Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab).
Bruna Lavinas Sayed PiccianiArkadiusz DziedzicJuliana Tristão WerneckMarcello Alves MarinhoThaylla Núñez Amin DickNara Regina QuintanilhaEliane Pedra DiasPublished in: BMC oral health (2021)
Patients undergoing treatment with IL-17 blockers, such as secukinumab, should be carefully monitored in order to avoid oral side effects resulting from the use of this medication.